Abbott agrees $670 million settlement in preterm formula litigation
Abbott said it reached a $670 million settlement with three law firms representing about 2,000 plaintiffs to partially resolve litigation alleging its specialty preterm formulas caused necrotizing enterocolitis. The deal includes resolution of a 2024 Illinois jury verdict that had awarded $495 million and follows a Missouri appeals court decision in May 2026; Abbott agreed to drop its appeal while denying liability. The company said roughly 1,700 lawsuits involve Abbott and Mead Johnson, and it still faces as many as 12,700 claims before duplicate and unsupported filings are removed. Federal cases are consolidated in Chicago while thousands remain in state courts.
Abbott agreed to a $670 million settlement to resolve lawsuits.
Context
A 2024 jury awarded $495 million to one plaintiff. A Missouri appeals court upheld that verdict in May 2026. The settlement could prompt more case resolutions or further trials.
The full analysis
19 dimensions on this story — world impact, market read, and what happens next.
- Full ContextLocked
- Affected SectorsLocked
- Stock ImpactLocked
- Economic IndicatorLocked
- Investor RelevanceLocked
- Professional RelevanceLocked
- Watch PointsLocked
- Probability of ChangeLocked
- Debate PointsLocked
- Prerequisite KnowledgeLocked
- Follow-up QuestionsLocked
- Pros & ConsLocked